Jump to main content
Jump to site search

Issue 40, 2015
Previous Article Next Article

A galactose-functionalized dendritic siRNA-nanovector to potentiate hepatitis C inhibition in liver cells

Author affiliations

Abstract

A RNAi based antiviral strategy holds the promise to impede hepatitis C viral (HCV) infection overcoming the problem of emergence of drug resistant variants, usually encountered in the interferon free direct-acting antiviral therapy. Targeted delivery of siRNA helps minimize adverse ‘off-target’ effects and maximize the efficacy of therapeutic response. Herein, we report the delivery of siRNA against the conserved 5′-untranslated region (UTR) of HCV RNA using a liver-targeted dendritic nano-vector functionalized with a galactopyranoside ligand (DG). Physico-chemical characterization revealed finer details of complexation of DG with siRNA, whereas molecular dynamic simulations demonstrated sugar moieties projecting “out” in the complex. Preferential delivery of siRNA to the liver was achieved through a highly specific ligand–receptor interaction between dendritic galactose and the asialoglycoprotein receptor. The siRNA-DG complex exhibited perinuclear localization in liver cells and co-localization with viral proteins. The histopathological studies showed the systemic tolerance and biocompatibility of DG. Further, whole body imaging and immunohistochemistry studies confirmed the preferential delivery of the nucleic acid to mice liver. Significant decrease in HCV RNA levels (up to 75%) was achieved in HCV subgenomic replicon and full length HCV-JFH1 infectious cell culture systems. The multidisciplinary approach provides the ‘proof of concept’ for restricted delivery of therapeutic siRNAs using a target oriented dendritic nano-vector.

Graphical abstract: A galactose-functionalized dendritic siRNA-nanovector to potentiate hepatitis C inhibition in liver cells

Back to tab navigation

Supplementary files

Publication details

The article was received on 04 May 2015, accepted on 14 Aug 2015 and first published on 28 Sep 2015


Article type: Paper
DOI: 10.1039/C5NR02898A
Citation: Nanoscale, 2015,7, 16921-16931
  • Open access: Creative Commons BY-NC license
  •   Request permissions

    A galactose-functionalized dendritic siRNA-nanovector to potentiate hepatitis C inhibition in liver cells

    A. Lakshminarayanan, B. U. Reddy, N. Raghav, V. K. Ravi, A. Kumar, P. K. Maiti, A. K. Sood, N. Jayaraman and S. Das, Nanoscale, 2015, 7, 16921
    DOI: 10.1039/C5NR02898A

    This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence. Material from this article can be used in other publications provided that the correct acknowledgement is given with the reproduced material and it is not used for commercial purposes.

    Reproduced material should be attributed as follows:

    • For reproduction of material from NJC:
      [Original citation] - Published by The Royal Society of Chemistry (RSC) on behalf of the Centre National de la Recherche Scientifique (CNRS) and the RSC.
    • For reproduction of material from PCCP:
      [Original citation] - Published by the PCCP Owner Societies.
    • For reproduction of material from PPS:
      [Original citation] - Published by The Royal Society of Chemistry (RSC) on behalf of the European Society for Photobiology, the European Photochemistry Association, and RSC.
    • For reproduction of material from all other RSC journals:
      [Original citation] - Published by The Royal Society of Chemistry.

    Information about reproducing material from RSC articles with different licences is available on our Permission Requests page.

Search articles by author

Spotlight

Advertisements